Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache
Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Galcanezumab (Emgality
®
) is a humanized monoclonal antibody targeting the calcitonin gene-related peptide (CGRP), thereby inhibiting its physiological activity, with CGRP playing a key role in the pathophysiology of migraine and headache disorders. In pivotal phase 3 trials, recommended dosages of subcutaneous galcanezumab once monthly were...
Alternative Titles
Full title
Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2410370579
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2410370579
Other Identifiers
ISSN
0012-6667
E-ISSN
1179-1950
DOI
10.1007/s40265-020-01329-5
